Zydus and Lupin sign licensing agreement for co-marketing of Saroglitazar Mg
Zydus Lifesciences Limited a discovery-driven, global lifesciences company and Lupin Limited (Lupin), a global pharma major, announced that they have entered into a licensing and supply agreement to co-market, Saroglitazar Mg for the treatment of Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steato Hepatitis (NASH) in India. With a once daily, 4mg dose regimen, Saroglitazar Mg enables better compliance, reduces the pill burden and offers the patient more convenience.